AstraZeneca PLC has exhibited notable stock market activities including, substantial share transactions, upgrades in ratings and stocks reaching an all-time high. Many entities increased their stakes in AstraZeneca, such as
Hilltop National Bank, QP Wealth Management, LLC, TD Cowen, Bank of America Corp DE, and
Fayez Sarofim & Co. The company's overall stock rating increased as a result of its robust
pipeline strength. AstraZeneca also accomplished a direct listing of ordinary shares and US debt securities on the New York Stock Exchange, which led to an exceptional rise in their stock prices. Analysts have given an average rating of 'Moderate Buy' to the biopharmaceutical giant. Furthermore,
Morgan Stanley uplifted AstraZeneca's stock price target based on growth in earnings, categorizing it as one of the best Pharma stocks to invest in. The company's shares also launched on the NYSE, hitting a record high. While there has been a significant rally in AstraZeneca's shares, some investors question if this rally is sustainable over the long term.
AstraZeneca Stocks News Analytics from Fri, 22 Aug 2025 07:00:00 GMT to Sat, 21 Mar 2026 11:00:53 GMT -
Rating 8
- Innovation 5
- Information 8
- Rumor 2
